Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | CCR2 | P41597 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12021512 | 0.82 | USP2 (0.53) | USP2SMN1; SMN2RECQLCHRM2CHRM1 | |
| SCHEMBL315706 | 0.82 | USP2 (0.53) | USP2SMN1; SMN2RECQLCHRM2CHRM1 | |
| SCHEMBL925405 | 0.82 | USP2 (0.53) | USP2SMN1; SMN2RECQLCHRM2CHRM1 | |
| SCHEMBL12021701 | 0.82 | USP2 (0.53) | USP2SMN1; SMN2RECQLCHRM2CHRM1 | |
| SCHEMBL8099609 | 0.81 | USP2 (0.51) | USP2SMN1; SMN2RECQLCHRM2CHRM1 | |
| SCHEMBL14410373 | 0.81 | USP2 (0.51) | USP2SMN1; SMN2RECQLCHRM2CHRM1 | |
| SCHEMBL24923288 | 0.80 | USP2 (0.47) | USP2SMN1; SMN2RECQLCHRM2CHRM1 | |
| SCHEMBL15561483 | 0.80 | USP2 (0.47) | USP2SMN1; SMN2RECQLCHRM2CHRM1 | |
| SCHEMBL25849506 | 0.80 | SMN1; SMN2 (0.47) | USP2SMN1; SMN2RECQLHSD17B10CA12 | |
| SCHEMBL15561481 | 0.80 | USP2 (0.47) | USP2SMN1; SMN2RECQLCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093400-B2 | Compounds useful in therapy | PFIZER INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100317652-A1 | Compounds Useful In Therapy | PFIZER INC | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317652-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | USP2 4525/4885SMN1; SMN2 4519/4885RECQL 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.